Overview

Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Status:
Not yet recruiting

Trial end date:
2022-01-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of the study drug known as KH903 in participants with gastric and gastroesophageal cance

Phase:

Phase 2

Details

Lead Sponsor:

Chengdu Kanghong Biotech Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel